Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates

分组1 - Acadia Pharmaceuticals reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing a significant increase from $0.01 per share a year ago, representing an earnings surprise of 25% [1] - The company achieved revenues of $241.96 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 2.85%, and up from $165.24 million year-over-year [1] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $251.11 million, while for the current fiscal year, the estimate is $0.58 on revenues of $952.88 million [4] - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - G1 Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of -221.4%, with revenues anticipated to be $15.88 million, down 62.6% from the previous year [5][6]